Anti-VEGFR2 monoclonal antibody

Ramucirumab (Specialist drug)

Brand names: Cyramza

Ramucirumab is an intravenous monoclonal antibody used as a specialist anti-angiogenic treatment in gastric, colorectal and non-small-cell lung cancers.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds vascular endothelial growth factor receptor 2 (VEGFR-2), blocking VEGF ligand binding and inhibiting tumour angiogenesis.

Prescribing in practice

As a VEGF-pathway inhibitor it carries a risk of serious haemorrhage, gastrointestinal perforation and impaired wound healing, so it should be withheld around surgery.
Hypertension is common and should be controlled before and monitored during treatment.
Infusion-related reactions can occur and administration is confined to specialist oncology day units.

Monitoring

Monitor blood pressure, urinary protein and for signs of bleeding or gastrointestinal perforation during treatment.

Counselling the patient

Report severe abdominal pain, black stools, or any significant bleeding urgently.
Tell the team before any planned surgery or dental procedure.
Have your blood pressure checked as arranged.

Evidence & guidelines

Use is supported by NICE guidance and pivotal phase III trials in the relevant tumour types.

Reference: NICE TA378/TA439; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways